Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1113 participants.
Also called NCT05772169
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,113 participants
- Sponsor
- Registry
-
NCT05772169
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05772169. Randomized; triple masking; primary purpose treatment. Start 2023-03-31 (actual); primary completion 2024-11-19 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
- Condition
- Hypercortisolism
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Mifepristone 300 MG [Korlym]
- Intervention (Drug)
- Placebo for mifepristone
- Lead sponsor
- Corcept Therapeutics
Record details
- Record id
cardio:ct-nct05772169- Content hash
a2db7d54feec9289af5ec03bc5d57d6c0b87187847f2dd73512b19891b7de6f4